Search

Introduction: Little is known about COVID-19 vaccination intent among people experiencing homelessness. This study assesses surveyed COVID-19 vaccination intent among adult homeless shelter residents and staff and identifies factors associated with vaccine deliberation (responded "undecided") and reluctance (responded "no"), including time trends., Methods: From 11/1/2020-2/28/21, we conducted repeated cross-sectional surveys at nine shelters in King County, WA as part of ongoing community-based SARS-CoV-2 surveillance. We used a multinomial model to identify characteristics associated with vaccine deliberation and reluctance., Results: A total of 969 unique staff (n = 297) and residents (n = 672) participated and provided 3966 survey responses. Among residents, 53.7% (n = 361) were vaccine accepting, 28.1% reluctant, 17.6% deliberative, and 0.6% already vaccinated, whereas among staff 56.2% were vaccine accepting, 14.1% were reluctant, 16.5% were deliberative, and 13.1% already vaccinated at their last survey. We observed higher odds of vaccine deliberation or reluctance among Black/African American individuals, those who did not receive a seasonal influenza vaccine, and those with lower educational attainment. There was no significant trend towards vaccine acceptance., Conclusions: Strong disparities in vaccine intent based on race, education, and prior vaccine history were observed. Increased vaccine intent over the study period was not detected. An intersectional, person-centered approach to addressing health inequities by public health authorities planning vaccination campaigns in shelters is recommended. Clinical Trial Registry Number: NCT04141917., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Helen Y. Chu reports financial support was provided by Centers for Disease Control and Prevention. James P. Hughes reports a relationship with National Institutes of Health that includes: funding grants. Michael L. Jackson, Janet A. Englund, Helen Y. Chu reports a relationship with Sanofi Pasteur that includes: consulting or advisory and funding grants. Michael Boeckh reports a relationship with Moderna Therapeutics Inc that includes: consulting or advisory. Michael Boeckh reports a relationship with VirBio that includes: consulting or advisory and funding grants. Michael Boeckh, Janet A. Englund, Helen Y. Chu reports a relationship with Merck & Co Inc that includes: consulting or advisory and funding grants. Michael Boeckh reports a relationship with Regeneron Pharmaceuticals Inc that includes: funding grants. Michael Boeckh reports a relationship with Ridgeback Biotherapeutics L.P. that includes: funding grants. Michael Boeckh, Helen Y. Chu reports a relationship with Bill and Melinda Gates Foundation that includes: consulting or advisory and funding grants. Janet A. Englund reports a relationship with AstraZeneca that includes: consulting or advisory and funding grants. Janet A. Englund, Helen Y. Chu reports a relationship with GlaxoSmithKline that includes: consulting or advisory and funding grants. Janet A. Englund reports a relationship with Novavax Inc that includes: funding grants. Janet A. Englund, Helen Y. Chu reports a relationship with Pfizer Inc that includes: consulting or advisory and funding grants. Janet A. Englund reports a relationship with Meissa Vaccines that includes: consulting or advisory. Helen Y. Chu reports a relationship with Ellumen Inc that includes: consulting or advisory and funding grants. Helen Y. Chu reports a relationship with Gates Ventures that includes: funding grants. Helen Y. Chu reports a relationship with Cepheid that includes: funding grants.]., (Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)